Without such trials, it is not possible to definitively establish what dose BPC-157 do in the human body, what an appropriate human research framework would look like, what the human safety profile is, or what conditions if any it might effectively address in clinical practice
Contraindications Based on mechanisms and theoretical considerations, BPC-157 may not be appropriate for: Individuals with active cancer Pregnant or breastfeeding women Those with uncontrolled cardiovascular conditions People taking anticoagulant medications (effects on bleeding unknown) Individuals with autoimmune conditions (immune modulation effects unclear) Quality and Purity Concerns Perhaps the most significant safety concern involves product quality
It is contraindicated in patients with active malignancy or diabetic retinopathy
Disclaimer: These statements are based on emerging research and are not intended to suggest diagnosis, treatment, or cure
Outcome: Achieved 20/25 vision by 3 months, faster than typical recovery